Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily metabolized by hepatic CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to non-linear pharmacokinetics.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40% bound, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3–0.7 L/kg (mean 0.45 L/kg). Higher Vd in neonates (0.6–0.9 L/kg) and patients with cirrhosis. Vd approximates total body water; distribution is rapid into well-perfused tissues, less into adipose tissue.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 96%–100% (almost complete). Oral sustained-release: 80%–100% (variable due to formulation-dependent release; food may increase rate but not extent for some products). Rectal: variable, approximately 80–90% (solution/suppository dependent).
Oral: 40-50%; Inhalation: 20-30%
No dose adjustment required for GFR > 10 m L/min; for GFR < 10 m L/min, reduce dose by 50% and monitor serum levels
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use or use with extreme caution and monitor levels
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Initial 5 mg/kg/day in divided doses every 6-8 hours, titrate based on serum levels; typical maintenance: 1-12 years: 20 mg/kg/day (max 800 mg/day), >12 years: 16 mg/kg/day (max 900 mg/day)
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (e.g., 300 mg/day extended-release) with frequent monitoring due to decreased clearance; avoid doses exceeding 400 mg/day without serum level guidance
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning for theophylline.
No FDA black box warning.
Narrow therapeutic index; monitor serum levels. Risk of cardiac arrhythmias and seizures, especially at high levels. Use with caution in patients with cardiac disease, hepatic impairment, or those receiving other methylxanthines.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation. Concurrent use of other methylxanthines.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
High-carbohydrate, low-protein diets can increase theophylline toxicity by reducing clearance. Charcoal-broiled meats and cruciferous vegetables (broccoli, Brussels sprouts, kale) may increase metabolism, potentially reducing efficacy. Avoid large amounts of caffeine-containing products (coffee, tea, cola, energy drinks) as they can exacerbate CNS and cardiac adverse effects.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No known teratogenic effects; however, neonatal withdrawal (irritability, jitteriness, apnea) may occur with third-trimester exposure. High maternal levels may be associated with fetal tachycardia and intrauterine growth restriction.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7. Infant exposure is estimated at 1-10% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability or jitteriness. The American Academy of Pediatrics considers it compatible with breastfeeding, but risk-benefit assessment should be individualized.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Theophylline clearance decreases in the third trimester, leading to prolonged half-life. Dose reduction of 20-30% may be required to avoid toxicity. Monitor serum levels frequently (at least every 2-4 weeks) and adjust dose to maintain therapeutic concentrations. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring upward dose adjustment.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels closely, especially when interacting drugs (e.g., cimetidine, fluoroquinolones, macrolides) are added or removed. Use with caution in patients with hepatic impairment, heart failure, or COPD exacerbation as clearance decreases. Cigarette smoking induces metabolism, requiring dose adjustments. Slow IV infusion over 20-30 minutes to avoid hypotension and arrhythmias.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose or stop without consulting your doctor.,Avoid smoking or use of nicotine products as they alter theophylline levels.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Store medication at room temperature away from moisture and heat.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
"Theophylline, a cytochrome P450 (CYP) 1A2 substrate and inhibitor, may reduce the metabolic clearance of lobeglitazone, which is primarily metabolized by CYP1A2. This can lead to increased plasma concentrations of lobeglitazone, potentially enhancing its therapeutic effects and risk of adverse events such as peripheral edema, weight gain, and hypoglycemia. Clinically, patients receiving both drugs should be monitored for signs of lobeglitazone toxicity, and dose adjustments may be necessary."
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, inhibits CYP1A2 isoenzyme activity, which is the primary metabolic pathway for theophylline. Concomitant administration can lead to a significant increase in theophylline serum concentrations, elevating the risk of theophylline toxicity, including nausea, vomiting, cardiac arrhythmias, and seizures. Clinical monitoring and dose adjustment of theophylline are necessary to avoid adverse effects."
"Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may decrease the metabolic clearance of theophylline, a xanthine derivative bronchodilator, through competitive inhibition of cytochrome P450 (CYP) 1A2 enzymes. This interaction can lead to elevated serum theophylline concentrations, increasing the risk of theophylline toxicity, which may manifest as nausea, vomiting, arrhythmias, or seizures. Clinical monitoring and dose adjustment of theophylline are warranted to prevent adverse outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL vs AEROLATE III, answered by our medical review team.
THEOPHYL is a Bronchodilator that works by Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL is: 300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL is classified as Category C. Theophylline is not considered a major human teratogen. First trimester: Limited data show no increased risk of major malformations above baseline. Second and third trimesters: No . AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.